Using Rational Drug Design Toward the Synthesis of Novel Flavonoid Derivatives as Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease

Presentation Author(s) Information

Jennifer Minnick, Georgia College and State University

Abstract

Research has shown that the neurotransmitter acetylcholine (Ach) is less expressed in the brainof Alzheimer's patients when compared to normal patient's levels. It is proposed that thisdecrease stems from the hydrolysis of Ach by the enzyme acetylcholinesterase. As a result,acetylcholinesterase inhibitors have been identified as a viable option for the treatment of varioussymptoms associated with cognitive function in patients with Alzheimer's disease. Flavonoids,natural products that exhibit acetylcholinesterase inhibitory activity, can potentially serve aspromising leads for the treatment of Alzheimer's disease. Through the use of rational drugdesign, this research project will investigate the design and synthesis of novel flavonoidderivatives that incorporate nitrogen-containing fused heterocyclic rings, which were identifiedthrough SAR as crucial structural elements, in pursuance of an effective treatment ofAlzheimer's disease.

Session Name:

Poster Presentation Session #1 - Poster #47

Start Date

10-4-2015 11:30 AM

End Date

10-4-2015 12:15 PM

Location

HSB 3rd Floor Student Commons

This document is currently not available here.

Share

Import Event to Google Calendar

COinS
 
Apr 10th, 11:30 AM Apr 10th, 12:15 PM

Using Rational Drug Design Toward the Synthesis of Novel Flavonoid Derivatives as Acetylcholinesterase Inhibitors for the Treatment of Alzheimer’s Disease

HSB 3rd Floor Student Commons

Research has shown that the neurotransmitter acetylcholine (Ach) is less expressed in the brainof Alzheimer's patients when compared to normal patient's levels. It is proposed that thisdecrease stems from the hydrolysis of Ach by the enzyme acetylcholinesterase. As a result,acetylcholinesterase inhibitors have been identified as a viable option for the treatment of varioussymptoms associated with cognitive function in patients with Alzheimer's disease. Flavonoids,natural products that exhibit acetylcholinesterase inhibitory activity, can potentially serve aspromising leads for the treatment of Alzheimer's disease. Through the use of rational drugdesign, this research project will investigate the design and synthesis of novel flavonoidderivatives that incorporate nitrogen-containing fused heterocyclic rings, which were identifiedthrough SAR as crucial structural elements, in pursuance of an effective treatment ofAlzheimer's disease.